BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 12124317)

  • 1. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production.
    Geschwind JF; Ko YH; Torbenson MS; Magee C; Pedersen PL
    Cancer Res; 2002 Jul; 62(14):3909-13. PubMed ID: 12124317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer.
    Vali M; Liapi E; Kowalski J; Hong K; Khwaja A; Torbenson MS; Georgiades C; Geschwind JF
    J Vasc Interv Radiol; 2007 Jan; 18(1 Pt 1):95-101. PubMed ID: 17296709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic intra-arterial injection of 3-bromopyruvate in rabbit VX2 tumor.
    Shin SW; Han H; Choo SW; Yoo BC; Park CK; Do YS; Lee JH; Lee DH; Choi D; Choo IW; Kim SS; Lee JY
    Acta Radiol; 2006 Dec; 47(10):1036-41. PubMed ID: 17135005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a new orthotopic animal model of metastatic liver cancer in the rabbit VX2 model: effect on metastases after partial hepatectomy, intra-arterial treatment with 3-bromopyruvate and chemoembolization.
    Vossen JA; Buijs M; Syed L; Kutiyanwala F; Kutiyanwala M; Geschwind JF; Vali M
    Clin Exp Metastasis; 2008; 25(7):811-7. PubMed ID: 18649116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor.
    Liapi E; Geschwind JF; Vali M; Khwaja AA; Prieto-Ventura V; Buijs M; Vossen JA; Ganapathy-Kanniappan S; Wahl RL
    J Nucl Med; 2011 Feb; 52(2):225-30. PubMed ID: 21233194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma.
    Schaefer NG; Geschwind JF; Engles J; Buchanan JW; Wahl RL
    Transl Res; 2012 Jan; 159(1):51-7. PubMed ID: 22153810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET for evaluating the antitumor effect of intraarterial 3-bromopyruvate administration in a rabbit VX2 liver tumor model.
    Park HS; Chung JW; Jae HJ; Kim YI; Son KR; Lee MJ; Park JH; Kang WJ; Yoon JH; Chung H; Lee K
    Korean J Radiol; 2007; 8(3):216-24. PubMed ID: 17554189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.
    Ko YH; Smith BL; Wang Y; Pomper MG; Rini DA; Torbenson MS; Hullihen J; Pedersen PL
    Biochem Biophys Res Commun; 2004 Nov; 324(1):269-75. PubMed ID: 15465013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: In vivo investigation in normal rabbit model.
    Chang JM; Chung JW; Jae HJ; Eh H; Son KR; Lee KC; Park JH
    Acad Radiol; 2007 Jan; 14(1):85-92. PubMed ID: 17178370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adriamycin thermotherapy through hepatic artery for model of VX2 carcinoma in rabbit liver].
    Zhang HX; Liu Y; Cao W; Wang ZM; Guo WP; Ni DH; Liu YY; Wang YQ; Li WX; Fan AL; Han RY
    Ai Zheng; 2002 Aug; 21(8):843-5. PubMed ID: 12478889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice.
    Zhang Y; Ma H; Zhang J; Liu S; Liu Y; Zheng D
    Life Sci; 2008 Jun; 82(23-24):1154-61. PubMed ID: 18485417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antitumor effect and hepatotoxicity of a hexokinase II inhibitor 3-bromopyruvate: in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model.
    Jae HJ; Chung JW; Park HS; Lee MJ; Lee KC; Kim HC; Yoon JH; Chung H; Park JH
    Korean J Radiol; 2009; 10(6):596-603. PubMed ID: 19885316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer.
    Hong K; Khwaja A; Liapi E; Torbenson MS; Georgiades CS; Geschwind JF
    Clin Cancer Res; 2006 Apr; 12(8):2563-7. PubMed ID: 16638866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of intra-arterial infusion of 3-bromopyruvate on metastases and survival benefit of hepatic VX2 tumor in rabbits].
    Jiang XY; Zhang XP; Huang JH; Luo RG; Miao BJ; Wang Y
    Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(39):3139-42. PubMed ID: 24417996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and growth suppressive effect of intra-hepatic arterial injection of AdCMV-p53 combined with CDDP to rat liver metastatic tumors.
    Okimoto T; Yahata H; Itou H; Shinozaki K; Tanji H; Sakaguchi T; Asahara T
    J Exp Clin Cancer Res; 2003 Sep; 22(3):399-406. PubMed ID: 14582698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents.
    Studeny M; Marini FC; Dembinski JL; Zompetta C; Cabreira-Hansen M; Bekele BN; Champlin RE; Andreeff M
    J Natl Cancer Inst; 2004 Nov; 96(21):1593-603. PubMed ID: 15523088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: a biodistribution and survival study.
    Vali M; Vossen JA; Buijs M; Engles JM; Liapi E; Ventura VP; Khwaja A; Acha-Ngwodo O; Ganapathy-Kanniappan S; Syed L; Wahl RL; Geschwind JF
    J Pharmacol Exp Ther; 2008 Oct; 327(1):32-7. PubMed ID: 18591216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate.
    Pereira da Silva AP; El-Bacha T; Kyaw N; dos Santos RS; da-Silva WS; Almeida FC; Da Poian AT; Galina A
    Biochem J; 2009 Feb; 417(3):717-26. PubMed ID: 18945211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproate sensitizes human glioblastoma cells to 3-bromopyruvate-induced cytotoxicity.
    Ishiguro Y; Kobayashi M; Ideno M; Narumi K; Furugen A; Iseki K
    Int J Pharm; 2018 Nov; 551(1-2):97-102. PubMed ID: 30138705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microenvironment of Morris hepatoma 5123 metastases to the lungs--ultrastructural analysis of intratumour injections of rhTNF-alpha.
    Nowak HF; Terlikowski S; Musiatowicz B; Sulkowska M; Sulkowski S
    Rocz Akad Med Bialymst; 1997; 42 Suppl 2():95-101. PubMed ID: 9646688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.